Moonlight Bio

Executive Summary

Moonlight Bio is a San Diego-based preclinical biotechnology company founded in 2021 with a mission to leverage evolutionary biology to develop superior T cell therapies for cancer. By studying natural T cell adaptations, the company aims to engineer T cells with enhanced proliferation, persistence, and antitumor function, potentially achieving unprecedented outcomes for patients. While still in early stages with no disclosed funding or pipeline details, Moonlight Bio's differentiated approach addresses key limitations of current CAR-T and TCR therapies. The company's focus on harnessing evolutionary forces could yield T cell products with intrinsic advantages over conventional engineering methods. As a private, preclinical entity, Moonlight Bio faces significant development and funding risks, but its scientific premise and the growing demand for next-generation cell therapies position it as a potential candidate for partnerships or investment pending proof-of-concept data.

Upcoming Catalysts (preview)

• Q4 2026IND submission for lead T cell therapy candidate50% success
• H1 2026Presentation of preclinical efficacy data at major conference (e.g., ASGCT, SITC)70% success
• Q3 2026Strategic partnership or licensing deal with larger biopharma40% success